In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography

被引:74
作者
Aboagye, EO [1 ]
Price, PM [1 ]
Jones, T [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp,Sch Med, MRC Cycltron Unit, PET Oncol Grp,Dept Canc Med, London W12 0NN, England
关键词
D O I
10.1016/S1359-6446(01)01684-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Positron-emission tomography (PET) is a sensitive technique that can be used to measure drug pharmacokinetics and pharmacodynamics noninvasively in target tissues of patients. Here we focus on the application of this technology to address some of the bottlenecks in drug development, including: elucidation of pathophysiology: evaluation of pharmacokinetics, proof of principle of mechanism, and assessment of efficacy and/or response to therapy.
引用
收藏
页码:293 / 302
页数:10
相关论文
共 48 条
[41]  
Tjuvajev JG, 1998, CANCER RES, V58, P4333
[42]  
Tozer GM, 1999, CANCER RES, V59, P1626
[43]   METABOLIC MONITORING OF BREAST-CANCER CHEMOHORMONOTHERAPY USING POSITRON EMISSION TOMOGRAPHY - INITIAL EVALUATION [J].
WAHL, RL ;
ZASADNY, K ;
HELVIE, M ;
HUTCHINS, GD ;
WEBER, B ;
CODY, R .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2101-2111
[44]   The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro [J].
Waki, A ;
Kato, H ;
Yano, R ;
Sadato, N ;
Yokoyama, A ;
Ishii, Y ;
Yonekura, Y ;
Fujibayashi, Y .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (07) :593-597
[45]  
WELLS P, 1997, P AM SOC CLIN ONCOL, V15, pA548
[46]  
Workman P., 1995, PET for Drug Development and Evaluation, P277
[47]   Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography:: Review and 1999 EORTC recommendations [J].
Young, H ;
Baum, R ;
Cremerius, U ;
Herholz, K ;
Hoekstra, O ;
Lammertsma, AA ;
Pruim, J ;
Price, P .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) :1773-1782
[48]  
[No title captured]